Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 16, 2004. The report details corporate actions regarding share capital, including share buybacks, new share issuances for employee plans, and changes in directors' interests in company shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on specific transactional data related to share capital:
- Share Buyback: 2,200,000 Ordinary 25 pence shares purchased for cancellation on March 11, 2004, at 1,089.8 pence per share.
- New Issuances: Application made for block listings totaling 185,185 Ordinary shares (25p each) for employee share option plans.
- ADR Trading: US Retirement Savings Plan ADR holdings fluctuated between 18,651,455 and 18,925,448 shares during the period, with average transaction prices of $39.49 and $40.00.
Material Changes
Material changes reported in this filing are limited to capital structure adjustments and director holdings:
- Capital Reduction: The company executed a share buyback of 2.2 million shares for cancellation.
- Capital Increase: The company sought approval to issue approximately 185,000 new shares to satisfy obligations under three distinct employee share option schemes.
- Director Holdings: Minor changes in director interests were noted due to movements in the GSK Employee Trust and the US Retirement Savings Plan. Specific increases were recorded for Dr. J.P. Garnier (6 ADRs) and Dr. T. Yamada (108 ADRs) on March 12, 2004.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. The document is a procedural report of regulatory disclosures regarding share transactions and director interests.
Investor Verification Checklist
- Verify the total cost of the 2.2 million share buyback (2,200,000 shares x 1,089.8 pence).
- Confirm the final approval status of the 185,185 new share block listings with the UK Listing Authority.
- Review the full terms of the SmithKline Beecham 1989 Executive Share Option Plan and the GlaxoSmithKline Savings Related Share Option Scheme to understand dilution impact.
- Check subsequent filings for the impact of these share movements on the company's total outstanding share count and earnings per share.